(NASDAQ: PCVX) Vaxcyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Vaxcyte's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PCVX's revenue for 2026 to be $19,473,503,250, with the lowest PCVX revenue forecast at $19,473,503,250, and the highest PCVX revenue forecast at $19,473,503,250. On average, 1 Wall Street analysts forecast PCVX's revenue for 2027 to be $1,856,473,977, with the lowest PCVX revenue forecast at $1,856,473,977, and the highest PCVX revenue forecast at $1,856,473,977.
In 2028, PCVX is forecast to generate $14,949,159,328 in revenue, with the lowest revenue forecast at $1,856,473,977 and the highest revenue forecast at $28,041,844,680.